Synonyms: BAY-1125976 | Example 5 [WO2012136776A1]
Compound class:
Synthetic organic
Comment: BAY1125976 is an allosteric inhibitor of AKT1 and AKT2 that is being developed by Bayer for oncology potential. It is claimed as example 5 in Bayer's patent WO2012136776A1 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bärfacker L, Scott W, Hägebarth A, Ince S, Rehwinkel H, Politz O, Neuhaus R, Briem H, Bömer U. (2012)
Imidazopyridazines as Akt kinase inhibitors. Patent number: WO2012136776A1. Assignee: Bayer Pharma AG. Priority date: 07/04/2011. Publication date: 11/10/2012. |
2. Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M et al.. (2019)
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel), 11 (12). DOI: 10.3390/cancers11121987 [PMID:31835495] |